Xenotransplantation - 2000

Journal of Clinical Pathology

Volumn 53, Issue 1, 2000, Pages 44-48

  Goddard, M J ^a   Foweraker, J E ^a   Wallwork, J ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRAFT INFECTION; GRAFT REJECTION; IMMUNOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SWINE; XENOTRANSPLANTATION;

ANIMALS; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; SWINE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS; ZOONOSES;

EID: 0033980944     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.1.44     Document Type: Review

References (57)

1. Matesanz R, Miranda B, Felipel C, Naya MT. Continuous improvement in organ donation. Transplantation 1996;61:1119-21.
2. Cohen B, D'Amaro J, De Meester J, et al. Changing patterns in organ transplantation in Eurotransplant 1990-1996. Transplant Int 1997;10:1-6.
3. Novitsky D, Cooper DK, Reichart B. Haemodynamic and metabolic responses to hormonal therapy in brain dead potential organ donors. Transplantation 1997;43:852-4.
4. Pratschke J, Wilhelm MJ, Kusak M, et al. Brain death and its influence on donor quality. Transplantation 1999;67:343-8.
5. White D, Langford G, Cozzi E, et al. Production of pigs transgenic for human DAF. A strategy for human xenotransplantation. Xenotransplantation 1995;2:213-18.
6. Crick SJ, Sheppard MN, Ho SW, et al. Anatomy of the pig heart: comparisons with normal human cardiac structure. J Anat 1998;193:105-19.
7. Schmoeckel M, Bhatti F, Zaidi A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998;65:1570-7.
8. Hammer C, Linke R, Wagner F, et al. Organs from animals to man. Int Arch Allergy Immunol 1998;116:5-21.
9. Ido Y, Vindigni A, Chang K, et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997;277:563-6.
10. Zaidi A, Schmoeckel M, Bhatti F, et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998;65:1584-90.
11. Simon AR, Warrens AN, Sykes M. Efficacy of adhesive interactions in pig-to-human xenotransplantation. Immunol Today 1999;20:330-5.
12. Saadi S, Platt JL. Immunology of xenotransplantation. Life Sci 1998;62:365-87.
13. Galili U, Shohet SB, Kobrin E, et al. Man, apes and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988;263:17755-62.
14. Rose AG, Cooper DKC, Human PA, et al. Histopathology of hyperacute rejection of the heart - experimental and clinical observations in allografts and xenografts. J Heart Transplant 1991;10:223-34.
15. Platt JL, Vercellotti GM, Lindmann BJ, et al. Release of heparan sulphate from endothelial cells: implications for the pathogenesis of hyperacute rejection. J Exp Med 1990; 170:1363-8.
16. McEver RP, Beckstead JH, Moore KL, et al. GMP-140, a platelet alpha granule membrane protein is also synthesised by vascular endothelial cells and is localised in Weibelpalade bodies. J Clin Invest 1989;84:92-9.
17. Cooper DKC, Human PA, Lexer G, et al. Effect of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J Heart Transplant 1988; 7:238-46.
18. Levanthal JR, Dalmasoo AP, Cromwell JW, et al. Prolongation of xenograft survival by the depletion of complement. Transplantation 1993;55:857-66.
19. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994;57:363-70.
20. Candinas D, Lesinokski B, Robson SC, et al. Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation 1996;62:336-42.
21. Schmoekel M, Nollett G, Shahmohammadi M, et al. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Transplantation 1996;62:729-34.
22. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing CD59 and decay accelerating factor produce an intrinsic barrier to complement mediated damage. Transplantation 1997;63:149-55.
23. Leventhal JR, Matas AJ, Sun LH, et al. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993;56:1-8.
24. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998;101:1745-56.
25. McCurry KR, Parker W, Cotterell AH, et al. Humoral responses to pig-to-baboon cardiac transplantation: implications for the pathogenesis and treatment of acute vascular rejection and for accommodation. Hum Immunol 1997; 58:91-105.
26. Saadi S, Platt JI. Transient perturbation of endothelial cell integrity induced by antibodies and complement. J Exp Med 1995;181:21-31.
27. Saadi S, Holzknecht RA, Patte CP, et al. Complement mediated regulation of tissue factor activity in endothelium. J Exp Med 1995;182:1807-14.
28. Pober JS, Cotran RC. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427-51.
29. Blakely ML, Van der Werf WJ, Berndt MC, et al. Activation of intragraft endothelial cells and mononuclear cells during discordant xenograft rejection. Transplantation 1994;58: 1059-66.
30. Schleef RR, Bevilacqua MP, Sawdey M, et al. Cytokine activation of vascular endothelium. Effects on tissue type plasminogen activator and type-1 plasminogen activator inhibitor. J Biol Chem 1988;263:5797-803.
31. Fries JWU, Williams AJ, Atkins RC, et al. Expression of VCAM-1 and E-selectin in an in vivo model of endothelial cell activation. Am J Pathol 1993;143:725-37.
32. Schreck R, Albermann K, Bauerle PA. Nuclear factor κB: an oxidative stress responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992;17:221-37.
33. Inverardi L, Clissi B, Stolzer AL, et al. Human natural killer cells directly recognise evolutionary conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 1997;63:1318-30.
34. Malyguine AM, Saadi S, Platt JL, et al. Human natural killer cells induce morphologic changes in porcine endothelial cell monolayers. Transplantation 1996;61:161-4.
35. Goodman DJ, von Albertini M, Willson A, et al. Direct activation of porcine endothelial cells by human natural killer cells. Transplantation 1996;61:763-71.
36. Malyguine AM, Saadi S, Holzknecht RA, et al. induction of procoagulant function in porcine endothelial cells by human natural killer cells. J Immunol 1997;159:4659-64.
37. Millan MT, Geczy C, Stuhlmeier KM, et al. Human monocytes activate porcine endothelial cells resulting in increased E-selectin, interleukin-8, monocyte chemotactic protein-1 and plasminogen activator inhibitor-type-1 expression. Transplantation 1997;63:421-9.
38. Candinas D, Belliveau S, Koyamada N, et al. T cell independence of macrophage and natural killer cell infiltration, cytokine production and endothelial activation during delayed xenograft rejection. Transplantation 1996; 62:1920-7.
39. Alter BJ, Bach FH. Cellular basis of the proliferative response of human T-cells to mouse xenoantigens. J Exp Med 1990;171:333-8.
40. Eastlund T. Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection. Cell Transplant 1995;4:455-77.
41. Fishman JA. The risk of infection in xenotransplantation. Ann NY Acad Sci 1998;862:45-51.
42. Takeuchi Y, Liong SH, Bieniasz PD, et al. Sensitization of rhabdo-, lenti-, and spuma viruses to human serum by galactosyl(alpha1-3)galactosylation. J Virol 1997;71:6174-8.
43. Dorig RE, Marcil A, Richardson CD. CD46, a primate specific receptor for measles virus. Trends Microbiol 1994;2: 312-18.
44. Bergelson JM, Mohanty JG, Crowell RL, et al. Coxsackievirus B3 adapted to growth in RD cells binds to decay accelerating factor (CD55). J Virol 1995;69:1903-6.
45. Bergelson JM, Chan M, Solomon KR, et al. Decay accelerating factor (CD55), a glycosylphosphatidylinositol anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 1994;91:6245-9.
46. Weiss RA. Transgenic virus adaptation. Nature 1998;391: 327-8.
47. Centers for Disease Control and Prevention. Outbreak of Hendra-like virus - Malaysia and Singapore, 1998-1999. MMWR 1999;48:265-9.
48. Borie DC, Cramer DV, Phan-Thanh L, et al. Microbiological hazards related to xenotransplantation of porcine organs into man. Infect Control Hasp Epidemiol 1998;19: 355-65.
49. Fishman JA. Miniature swine as organ donors for man: strategies for prevention of xenotransplant associated infections. Xenotransplantation 1994;1:47-57.
50. Michaels MG, McMichael JP, Brasky K, et al. Screening donors for xenotransplantation. Transplantation 1994;57: 1462-5.
51. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nature Med 1997;3: 282-6.
52. Martin U, Kiessig V, Blusch JH, et al. Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet 1998;352: 692-4.
53. Heneine W, Tibell A, Switzer W, et al. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 1998;352: 695-9.
54. Patience C, Patton GS, Takeuchi Y, et al. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 1998;352: 699-701.
55. Paradis K, Langford G, Long Z, et al, and The Xen III Study Group. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissues. Science 1999;285:1236-41.
56. Weiss RA. Xenografts and retroviruses. Science 1999;285: 1221-2.
57. Bach FH, Fishman JA, Daniels N, et al. Uncertainty in xenotransplantation: individual benefit versus collective risk. Nature Med 1998;4:141-4.